Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

Setmelanotide for the treatment of obesity and hyperphagia caused by POMC or LEPR deficiency

Green Tea and Coffee Consumption Linked to Lower Mortality Risk in Diabetes

Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies

Regular use of PPIs was associated with a higher risk of type 2 diabetes and the risk increased with longer duration of use. Physicians should therefore exercise caution when prescribing PPIs, particularly for long-term use.

Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study

Metformin use is associated with early risk of anemia in individuals with type 2 diabetes, a finding consistent across two RCTs and replicated in one real-world study. The mechanism for this early fall in hemoglobin is uncertain, but given the time course, is unlikely to be due to vitamin B12 deficiency alone.

DIAMOND

Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial

6-week treatment with dapagliflozin did not affect proteinuria in patients with chronic kidney disease without diabetes, but did induce an acute and reversible decline in mGFR and a reduction in bodyweight.

Long-term clinical trials are underway to determine whether SGLT2 inhibitors can safely reduce the rate of major clinical kidney outcomes in patients with chronic kidney disease with and without diabetes.

https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30162-5/fulltext?rss=yes

In adults with type 2 diabetes, frequent hypoglycemic episodes were linked to a raised incidence of cardiovascular events in a recent retrospective study.

Type 1 Diabetes Prevention Moves Toward Reality

Prevention or delay of type 1 diabetes could become a reality in the next few years, with teplizumab (PRV-031, Provention Bio) likely to become the first agent commercially available to halt disease progression.

New data show that a single 14-day infusion of teplizumab, an anti-CD3 monoclonal antibody, leads to a median 3-year delay in type 1 diabetes onset among high-risk individuals compared with placebo, and follow last year's "game-changing" results showing a 2-year delay.

Metabolic Effects of Late Dinner in Healthy Volunteers—A Randomized Crossover Clinical Trial

Late Dinner Affects Metabolism, May Lead to Weight Gain, Diabetes

Eating a late dinner alters metabolic markers during sleep in a way that could lead to obesity or diabetes, according to the results of a small randomized crossover clinical trial, the Effect of Late Dinner on Nocturnal Metabolism.

LD induces nocturnal glucose intolerance, and reduces fatty acid oxidation and mobilization, particularly in earlier sleepers. These effects might promote obesity if they recur chronically.